Charles Webb

1.8k total citations · 1 hit paper
30 papers, 1.2k citations indexed

About

Charles Webb is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Charles Webb has authored 30 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Charles Webb's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Charles Webb is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Charles Webb collaborates with scholars based in United States and United Kingdom. Charles Webb's co-authors include John E. Edwards, John E. Bennett, Charles M. van der Horst, John Rex, A. Dine, Marcia J. Levenstein, Peter G. Pappas, Alan M. Sugar, W. Michael Scheld and Adolf W. Karchmer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Charles Webb

29 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

1994 786 citations John Rex, John E. Bennett et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Webb United States	13	717	577	310	223	127	30	1.2k
V. A. Morrison United States	14	1.2k 1.7×	1.0k 1.8×	291 0.9×	216 1.0×	76 0.6×	26	1.9k
Martin Schmidt‐Hieber Germany	26	509 0.7×	766 1.3×	629 2.0×	165 0.7×	70 0.6×	59	2.0k
D. J. Winston United States	21	395 0.6×	791 1.4×	322 1.0×	93 0.4×	156 1.2×	33	1.7k
Gloria Mattiuzzi United States	17	882 1.2×	896 1.6×	356 1.1×	187 0.8×	51 0.4×	36	1.4k
Z. Erjavec Netherlands	16	1.9k 2.6×	1.8k 3.1×	648 2.1×	377 1.7×	138 1.1×	24	2.5k
Marcia J. Levenstein United States	14	1.2k 1.6×	1.4k 2.4×	804 2.6×	185 0.8×	94 0.7×	15	2.1k
Ellis Tobin United States	20	431 0.6×	374 0.6×	156 0.5×	78 0.3×	85 0.7×	46	1.2k
Helen Leather United States	23	1.1k 1.5×	1.1k 1.9×	641 2.1×	162 0.7×	111 0.9×	49	2.3k
Gerald P. Bodey United States	11	393 0.5×	436 0.8×	571 1.8×	109 0.5×	120 0.9×	14	1.0k
A. Fernández‐Sevilla Spain	17	196 0.3×	458 0.8×	523 1.7×	128 0.6×	145 1.1×	24	1.3k

Countries citing papers authored by Charles Webb

Since Specialization

Citations

This map shows the geographic impact of Charles Webb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Webb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Webb more than expected).

Fields of papers citing papers by Charles Webb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Webb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Webb. The network helps show where Charles Webb may publish in the future.

Co-authorship network of co-authors of Charles Webb

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Webb. A scholar is included among the top collaborators of Charles Webb based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Webb. Charles Webb is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spigel, David R., Tarek Mekhail, David Waterhouse, et al.. (2017). First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). Cancer Investigation. 35(8). 541–546. 6 indexed citations

Hainsworth, John D., David Waterhouse, Dianna Shipley, et al.. (2013). Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium. Cancer Investigation. 31(5). 323–329. 19 indexed citations

Spigel, David R., F. Anthony Greco, David Waterhouse, et al.. (2012). Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer. Lung Cancer. 78(1). 70–75. 12 indexed citations

Yardley, DA, Carolyn B. Hendricks, Charles Webb, et al.. (2012). Abstract P1-14-14: Neoadjuvant Sunitinib (S) Administered with Weekly Paclitaxel (P)/Carboplatin(C) in Patients (Pts) with Locally Advanced Triple-Negative Breast Cancer (TNBC): Preliminary Results from a Phase I/II Trial of the Sarah Cannon Research Institute.. Cancer Research. 72(24_Supplement). P1–14. 1 indexed citations

Spigel, David R., F. Anthony Greco, Dana S. Thompson, et al.. (2010). Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 11(3). 198–203. 10 indexed citations

Spigel, David R., H.A. Burris, David Waterhouse, et al.. (2010). Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.. Journal of Clinical Oncology. 28(15_suppl). 7601–7601. 2 indexed citations

Yardley, Denise A., Howard A. Burris, Tiffanie Markus, et al.. (2009). Phase II Trial of Docetaxal Plus Imatinib Mesylate in the Treatment of Patients With Metastatic Breast Cancer. Clinical Breast Cancer. 9(4). 237–242. 28 indexed citations

Infante, Jeffrey R., Denise A. Yardley, Howard A. Burris, et al.. (2009). Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 9(1). 23–28. 15 indexed citations

Greco, F. Anthony, David R. Spigel, Dianna Shipley, et al.. (2007). Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network. Clinical Lung Cancer. 8(8). 483–487. 11 indexed citations

10.

Nicholson, Susan, et al.. (2002). Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagnostic Microbiology and Infectious Disease. 44(1). 109–116. 15 indexed citations

11.

Nicholson, Susan, et al.. (2002). Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 44(1). 117–125. 6 indexed citations

12.

Nicholson, Susan, Charles Webb, Vincent T. Andriole, Ronald N. Jones, & Walter R. Wilson. (2002). Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin. Diagnostic Microbiology and Infectious Disease. 44(1). 101–107. 4 indexed citations

13.

Gotfried, Mark H., et al.. (2002). Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study. Diagnostic Microbiology and Infectious Disease. 44(1). 85–91. 13 indexed citations

14.

Rauscher, H. Michael, Michael J. Young, Charles Webb, & Daniel J. Robison. (2000). Testing the Accuracy of Growth and Yield Models for Southern Hardwood Forests. Southern Journal of Applied Forestry. 24(3). 176–185. 15 indexed citations

15.

Rex, John, John E. Bennett, Alan M. Sugar, et al.. (1994). A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia. New England Journal of Medicine. 331(20). 1325–1330. 786 indexed citations breakdown →

16.

Sheehan, Daniel J., et al.. (1993). Antifungal Susceptibility Testing of Yeasts: A Brief Overview. Clinical Infectious Diseases. 17(Supplement_2). S494–S500. 54 indexed citations

17.

Hughes, Walter T., Philip A. Pizzo, James C. Wade, et al.. (1992). Evaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic Patients. Clinical Infectious Diseases. 15(Supplement_1). S206–S215. 81 indexed citations

18.

Talbert, J. T., et al.. (1980). Analysis of a Virginia Pine Seed Source Trial in the Interior South. Southern Journal of Applied Forestry. 4(3). 153–156. 1 indexed citations

19.

Webb, Charles & R. E. Farmer. (1968). Sycamore Seed Germination: The Effects of Provenance, Stratification, Temperature, and Parent Tree. 100. 6 indexed citations

20.

Zobel, Bruce J., et al.. (1960). Estimation of Certain Wood Properties of Loblolly and Slash Pine Trees from Breast Height Sampling. Forest Science. 6(2). 155–162. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact